Trial Profile
A prospective, cohort study investigating characteristics associated with adverse events in patients with chronic C virus hepatitis receiving ombitasvir/paritaprevir/ritonavir and dasabuvir and ribavirin
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 May 2017
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- 13 May 2017 New trial record
- 25 Apr 2017 Results presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases